Multiple sclerosis, relapsing-remitting Trials in Rennes, France
Conditions / Multiple sclerosis, relapsing-remitting / Rennes, France
Multiple sclerosis, relapsing-remitting has been the subject of sustained clinical investigation across multiple research sites.
14 total trials for this combination
Showing top 10 of 14 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT00459667 | BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose | COMPLETED | PHASE3 |
| NCT01420055 | Fingolimod -Response According to Coping - Evaluation | COMPLETED | PHASE4 |
| NCT00930553 | An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab | COMPLETED | PHASE3 |
| NCT03085810 | Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS) | TERMINATED | PHASE3 |
| NCT00099502 | BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients | COMPLETED | PHASE3 |
| NCT00027300 | Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis | COMPLETED | PHASE3 |
| NCT04756687 | Real World Analysis on Lymphocyte Reconstitution After Lymphopenia in Participants Treated by Tecfidera | COMPLETED | — |
| NCT03910738 | TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis | RECRUITING | PHASE2 |
| NCT00276341 | Study on the Effectiveness of EGb 761® vs Placebo Used for Cognitive Impairment in Patients With Multiple Sclerosis | COMPLETED | PHASE3 |
| NCT00548405 | Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two | COMPLETED | PHASE3 |